Novavax

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$4,000,000
Funder
Coalition for Epidemic Preparedness Innovations (CEPI)
Principal Investigator
Gregory Glenn
Research Location
United States of America
Lead Research Institution
Novavax
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

Antigen is recombinant full-length S protein nanoparticles engineered in baculovirus and expressed in Sf9 insect cells; Adjuvant is saponin-based Matrix-M (raw material sourced from tree bark from source in Chile)Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:5 days ago

View all publications at Europe PMC

Finding the dark matter: Large language model-based enzyme kinetic data extractor and its validation.

Health Expenditures Decline After Bariatric Surgery for Patients With Type 2 Diabetes.

The NuRD component CHD3 promotes BMP signalling during cranial neural crest cell specification.

3-year results of 0.01% and 0.1% loading dose atropine treatment including washout in Danish children with myopia: a placebo-controlled, randomised clinical trial.

Back from the brink: programmed cell revival for regeneration.

Highly stable and efficient copper(I) sensitizer for narrowband red organic light-emitting diodes with an operational lifetime (LT₉₅) of up to 3689 h at 1000 cd m^-2.

Harnessing TGF-β signaling to improve testicular organoid development from dissociated testicular cells.

Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle.

External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.